Cytotoxic T‑lymphocyte-associated antigen‑4 polymorphisms and susceptibility to cervical cancer: A meta‑analysis

Qiu,Hao; Tang,Weifeng; Yin,Pengfei; Cheng,Feng; Wang,Lixin

doi:10.3892/mmr.2013.1721

Cytotoxic T‑lymphocyte-associated antigen‑4 polymorphisms and susceptibility to cervical cancer: A meta‑analysis

Authors:
- Hao Qiu
- Weifeng Tang
- Pengfei Yin
- Feng Cheng
- Lixin Wang
View Affiliations

Affiliations: Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu 210008, P.R. China, Department of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212009, P.R. China
Published online on: October 11, 2013 https://doi.org/10.3892/mmr.2013.1721
Pages: 1785-1794

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytotoxic T‑lymphocyte associated antigen‑4 (CTLA‑4) polymorphisms have been examined for associations with cervical cancer in various countries. The results, however, are inconclusive. The present study aimed to explore whether CTLA‑4 +49 A/G, ‑318 C/T and CT60 G/A polymorphisms confer susceptibility to cervical cancer. A meta‑analysis was performed with 7,794 subjects included in 15 case‑control studies that were published up to January 1, 2013. The results from the meta‑analysis indicated that there were no significant associations between the risk of cervical cancer and the three studied polymorphisms [+49 A/G: Odds ratio (OR), 0.94 and 95% confidence interval (CI), 0.82‑1.07 for GG+AG vs. AA; ‑318 C/T: OR, 1.33 and 95% CI, 0.82‑2.16 for TT+TC vs. CC; and CT60: OR, 0.98 and 95% CI, 0.72‑1.33 for AA+AG vs. GG]. Stratified analyses by ethnicity for the +49 A/G and ‑318 C/T polymorphisms suggested that Asian populations had a decreased risk of cervical cancer for the +49 A/G polymorphism (OR, 0.75 and 95% CI, 0.58‑0.97 for GG+AG vs. AA), but an increased risk for the ‑318 C/T polymorphism (OR, 2.02 and 95% CI, 1.36‑3.00 for TC vs. CC). In summary, the current meta‑analysis showed that the +49 A/G and ‑318 C/T polymorphisms in CTLA‑4 constitute risk factors for cervical cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Stanley M: HPV - immune response to infection and vaccination. Infect Agent Cancer. 5:192010. View Article : Google Scholar : PubMed/NCBI
3	Moore EE, Wark JD, Hopper JL, Erbas B and Garland SM; CeCaGeEn Study Group. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. Twin Res Hum Genet. 15:79–86. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zoodsma M, Sijmons RH, de Vries EG and Zee AG: Familial cervical cancer: case reports, review and clinical implications. Hered Cancer Clin Pract. 2:99–105. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wank R and Thomssen C: High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature. 352:723–725. 1991. View Article : Google Scholar : PubMed/NCBI
6	Rahimifar S, Erfani N, Sarraf Z and Ghaderi A: ctla-4 gene variations may influence cervical cancer susceptibility. Gynecol Oncol. 119:136–139. 2010. View Article : Google Scholar : PubMed/NCBI
7	Matsumoto K, Oki A, Satoh T, et al: Interleukin-10 -1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 40:1113–1116. 2010. View Article : Google Scholar : PubMed/NCBI
8	Satinder K, Chander SR, Pushpinder K, Indu G and Veena J: Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population. Mol Cell Biochem. 315:151–157. 2008. View Article : Google Scholar : PubMed/NCBI
9	Teft WA, Kirchhof MG and Madrenas J: A molecular perspective of CTLA-4 function. Annu Rev Immunol. 24:65–97. 2006. View Article : Google Scholar : PubMed/NCBI
10	Buonavista N, Balzano C, Pontarotti P, Le Paslier D and Golstein P: Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics. 13:856–861. 1992. View Article : Google Scholar : PubMed/NCBI
11	Ligers A, Teleshova N, Masterman T, Huang WX and Hillert J: CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2:145–152. 2001. View Article : Google Scholar : PubMed/NCBI
12	Egen JG, Kuhns MS and Allison JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 3:611–618. 2002. View Article : Google Scholar : PubMed/NCBI
13	Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI
14	Hurwitz AA, Foster BA, Kwon ED, et al: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60:2444–2448. 2000.PubMed/NCBI
15	Curran MA and Allison JP: Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 69:7747–7755. 2009. View Article : Google Scholar : PubMed/NCBI
16	Hou R, Cao B, Chen Z, Li Y, et al: Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep. 37:515–520. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sun T, Zhou Y, Yang M, et al: Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res. 68:7025–7034. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lang C, Chen L and Li S: Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism and susceptibility to pancreatic cancer. DNA Cell Biol. 31:683–687. 2012.
19	Karabon L, Pawlak-Adamska E, Tomkiewicz A, et al: Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res. 18:219–226. 2012. View Article : Google Scholar : PubMed/NCBI
20	Karabon L, Pawlak E, Tomkiewicz A, et al: CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol. 72:947–954. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kamesh L, Heward JM, Williams JM, et al: CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology (Oxford). 48:1502–1505. 2009.
22	Heidari A, Noori Daloii MR, Keramatipour M, Rashikinezhad A, Sahmani AA and Amirzargar AA: CTLA-4 gene polymorphisms (−318C/T, +49A/G, +6230A/G) in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 9:219–223. 2010.
23	Li H, Zhou YF, Guo HY, Sun T, Zhang WH and Lin DX: Association between CTLA-4 gene polymorphism and susceptibility to cervical cancer. Zhonghua Zhong Liu Za Zhi. 33:681–684. 2011.(In Chinese).
24	Jiang L, Luo RY, Zhang W, Wang LR, Wang F and Cheng YX: Single nucleotide polymorphisms of CTLA4 gene and their association with human cervical cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 28:313–317. 2011.(In Chinese).
25	Hu L, Liu J, Chen X, et al: CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers - hepatocellular carcinoma and cervical cancer. Hum Immunol. 71:888–891. 2010.
26	Ivansson EL, Juko-Pecirep I and Gyllensten UB: Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 116:544–548. 2010. View Article : Google Scholar : PubMed/NCBI
27	Pawlak E, Karabon L, Wlodarska-Polinska I, et al: Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol. 71:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
28	Castro FA, Haimila K, Sareneva I, et al: Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population - a candidate gene approach. Int J Cancer. 125:1851–1858. 2009. View Article : Google Scholar : PubMed/NCBI
29	Su TH, Chang TY, Lee YJ, et al: CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis. 28:1237–1240. 2007. View Article : Google Scholar : PubMed/NCBI
30	Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ and de Geus-Oei LF: The role of [¹⁸F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 117:4582–4594. 2011.
31	Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS and Franco RF: 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 15:1956–1963. 2006. View Article : Google Scholar : PubMed/NCBI
32	Sousa H, Santos AM, Pinto D and Medeiros R: Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 20:731–741. 2007.PubMed/NCBI
33	de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC and do Amaral CM: Susceptibility to cervical cancer: an overview. Gynecol Oncol. 126:304–311. 2012.